注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Tenax Therapeutics Inc是一家專業製藥公司。該公司專注於識別和開發治療方法,以解決醫療需求高度未滿足的心肺疾病。該公司的產品包括TNX-103(口服左西孟旦)和TNX-201(口服腸溶伊馬替尼)。該公司的主導產品左西孟旦是一種鈣增敏劑/K-ATP激活劑,開髮用於急性失代償性心力衰竭住院患者的靜脈注射。TNX-201用於治療肺動脈高壓(PAH),PAH是一種致命的孤兒疾病。該公司已經完成了左西孟旦在北美的II期臨床試驗,該試驗用於治療射血分數保持不變的心力衰竭合併肺動脈高壓患者。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Daniel Burkhoff | - | 2018 | Member of PH-Left Heart Disease Scientific Advisory Board |
Sanjiv Shah | - | 2018 | Member of PH-Left Heart Disease Scientific Advisory Board |
Bradley Maron | - | - | Member of PAH Scientific Advisory Board |
Christopher T. Giordano | 49 | 2021 | CEO, President & Director |
Anna R. Hemnes | - | - | Member of PAH Scientific Advisory Board |
Declan Doogan | 72 | 2021 | Independent Director |
Gerald T. Proehl | 65 | 2014 | Independent Chairman |
Barry Borlaug | - | 2020 | Member of PH-Left Heart Disease Scientific Advisory Board |
Stuart Rich | 74 | 2018 | Chief Medical Officer & Director |
Robert P. Frantz | - | - | Member of PAH Scientific Advisory Board |
Michael Harvey Davidson | 68 | 2021 | Independent Director |
Robyn M. Hunter | 62 | 2022 | Independent Director |
June S. Almenoff | 67 | 2021 | Independent Director |
Javed Butler | - | 2023 | Member of PH-Left Heart Disease Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核